Monoclonal antibody successes in the clinic
Top Cited Papers
- 1 September 2005
- journal article
- Published by Springer Nature in Nature Biotechnology
- Vol. 23 (9) , 1073-1078
- https://doi.org/10.1038/nbt0905-1073
Abstract
Most monoclonal antibodies in clinical trials are owned by small biotech companies. But with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change.Keywords
This publication has 11 references indexed in Scilit:
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- Monoclonal antibodies marketNature Reviews Drug Discovery, 2004
- Monoclonal antibodies in the clinicNature Biotechnology, 2001
- Monoclonal antiendotoxin agent HA-1A (Centoxin)The Lancet, 1993
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986
- Human lymphocyte Hybridomas and Monoclonal AntibodiesPublished by Elsevier ,1986
- Production of functional chimaeric mouse/human antibodyNature, 1984
- Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.Proceedings of the National Academy of Sciences, 1984
- Human monoclonal antibodiesMolecular and Cellular Biochemistry, 1984
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975